PHVS — Pharvaris N.V.

Frequently asked questions about PHVS

How does DeepScreen analyze Pharvaris N.V.?

DeepScreen uses a 13-factor valuation and quality model. The methodology explains the inputs, weighting and limitations; model output is analytical research, not a personalized investment recommendation.

What is PHVS's P/E ratio?

A provider-backed P/E is currently unavailable. The defensible approach is to calculate or verify it from the latest price and reported trailing earnings rather than substitute a synthetic figure.

How should I assess Pharvaris N.V.'s profitability?

For Pharvaris N.V., the latest provider-backed snapshot shows net margin is 0.00%, ROE is -70.5%. Consistent profitability and healthy year-over-year growth should be confirmed over several reporting periods, with earnings reconciled to operating cash flow and one-off items removed from the analysis.

How much debt does Pharvaris N.V. have?

The latest provider-backed debt-to-equity ratio is 0.00x. Total debt is approximately $673,728, while cash is approximately $318.28M. Assess leverage together with interest expense, maturities and operating cash flow.

Is PHVS a buy?

DeepScreen provides research tools rather than a personalized recommendation. A decision should consider business quality, valuation, balance-sheet risk, disclosures, liquidity and your own objectives and risk tolerance.

How does the company make money?

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. This describes the company's disclosed business activity; for exact segment revenue, geography and customer concentration, use the latest annual report.

What is the company's competitive advantage (economic moat)?

Pharvaris N.V.'s potential moat should be evaluated from observable business economics: scale or cost advantages, network effects, switching costs, brand strength, patents or licences, distribution advantages and barriers to entry. The strongest evidence is a durable combination of pricing power, stable/growing margins and returns on capital over many years; a high ROE or ROCE alone does not prove a moat.

Who are the main competitors, and how does the company differ from them?

DeepScreen's directory-based comparison candidates include WAY (Waystar Holding Corp.), AUB (Atlantic Union Bankshares Corporation), EFT (Eaton Vance Floating Rate Income Trust Common Shares of Beneficial Interest), NXG (NXG NextGen Infrastructure Income Fund Common Shares of Beneficial Interest), MCI (Barings Corporate Investors). Sector labels and market-cap proximity can use inferred or modeled directory inputs; these candidates are not a verified list of direct competitors; the direct comparison should use products, customers, geography, margins, growth, returns on capital and valuation.

Are its products or services in long-term demand?

The provider classifies Pharvaris N.V. in Biotechnology. Long-term demand is supported when the underlying industry, customer base and product/service use remain durable over multiple years. For Pharvaris N.V., test that through multi-year revenue and customer trends, retention/repeat purchases where applicable, pricing power, capacity utilisation and the risk of substitution or technological disruption.

Who are its primary customers (individuals, businesses, or government)?

The provider's business profile describes Pharvaris N.V.'s activities as follows: Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Customer mix itself is not a stock-market ratio, so the primary customers should be confirmed from the company's segment, geographic and customer disclosures.

Is the company consistently profitable, and is its revenue growing year-over-year?

For Pharvaris N.V., the latest provider-backed snapshot shows net margin is 0.00%, ROE is -70.5%. Consistent profitability and healthy year-over-year growth should be confirmed over several reporting periods, with earnings reconciled to operating cash flow and one-off items removed from the analysis.

Does the company generate positive, healthy free cash flow?

The latest provider snapshot reports free cash flow of approximately $-90.36M, with operating cash flow of about $-155.19M. Whether that cash flow is healthy depends on persistence, conversion of profit to cash, capital expenditure needs and working-capital movements; inspect multiple periods rather than one TTM figure.

How high are the company's debt levels compared to its cash holdings and earnings?

The current snapshot shows D/E of 0.00x, debt of roughly $673,728, cash of roughly $318.28M, implying net debt of about $-317.61M. The full debt burden should be compared with EBITDA/EBIT, interest expense, maturities and recurring free cash flow.

How will the company finance its future growth or expansion projects?

Pharvaris N.V. currently has reported cash of about $318.28M and free cash flow of about $-90.36M. Those internal resources can contribute to expansion, while additional funding can come from operating cash flow, debt, equity issuance, asset sales or project finance. The exact funding mix for a specific project must come from management's disclosed plans.

What is the company's historical Return on Equity (ROE) and Return on Capital Employed (ROCE)?

The latest snapshot reports ROE of -70.5%no current live ROCE. Historical quality should be judged from a multi-year series and by checking whether returns remain above the company's cost of capital through different business conditions.

Who are the promoters or top executives running the company, and what is their track record?

The current provider profile lists these senior executives: Mr. Berndt Axel Edvard Modig CPA, M.B.A. (Co-Founder, CEO & Executive Director); Dr. Peng Lu M.D., Ph.D. (President); Mr. David W. Nassif J.D. (CFO, Chief Legal Officer & Corporate Secretary); Ms. Anna Nijdam M.Sc., R.A. (Head of Strategic Finance & Principal Accounting Officer); Dr. Stefan Abele Ph.D. (Chief Technology Operations Officer). Track record should be assessed through capital-allocation decisions, operating results, governance disclosures and execution against stated targets. For Indian companies, promoter identity and ownership should be checked against the latest exchange shareholding filing.

Is a high percentage of the promoter's stake pledged as collateral for loans?

Promoter pledge is a shareholding-disclosure item, not a normal valuation ratio. For an Indian company, check the latest exchange shareholding pattern and notes for pledged/encumbered promoter shares, and compare the percentage with prior quarters to identify changes. Do not infer pledge levels from debt-to-equity.

Does management have a transparent and honest history of communication with shareholders?

The strongest evidence is consistency between what management says and what later appears in reported results: guidance versus delivery, explanations for misses, treatment of related parties, restatements, capital allocation and disclosure of material risks. A multi-year record is needed; tone alone is not a reliable measure of transparency.

Has the firm ever faced corporate governance issues, legal troubles, or accounting scandals?

This question requires a dated event history. Review regulator orders, exchange notices, audited-report qualifications, court records and reputable reporting, and distinguish allegations or investigations from settlements and established findings. The absence of a warning label on a stock page is not proof that no historical event ever occurred.

Is the current stock valuation (such as the P/E or P/S ratio) reasonable or overpriced?

A live provider-backed P/E is not available and P/S is not currently available . These are descriptive multiples, not conclusions by themselves. A defensible valuation assessment compares the multiple with sustainable growth, margins, ROE/ROCE, balance-sheet risk, cyclicality and direct peers.

How does the company's valuation compare to its direct industry peers?

A practical peer set for Pharvaris N.V. starts with WAY (Waystar Holding Corp.), AUB (Atlantic Union Bankshares Corporation), EFT (Eaton Vance Floating Rate Income Trust Common Shares of Beneficial Interest), NXG (NXG NextGen Infrastructure Income Fund Common Shares of Beneficial Interest), MCI (Barings Corporate Investors). Compare the same reporting-period P/E, P/S and positive EV/EBITDA only when EBITDA supports a meaningful multiple, then adjust for growth, margin quality, leverage and business mix; a lower positive multiple is not automatically cheaper on an economic-value basis.

What is the margin of safety if market conditions or the economy worsens?

Margin of safety is created by buying with a gap between conservative intrinsic value and market price, then stress-testing the downside case. The relevant stress tests are lower revenue/earnings growth, lower margins, higher funding costs, weaker working capital and a lower terminal valuation. There is no universal fixed percentage that applies to every company.

Does the company pay a reliable dividend, or does it aggressively buy back its own shares?

The current provider-backed dividend yield is not available and payout ratio is 0.00% . Dividend reliability should be checked across several years and against free cash flow, while buyback intensity should be verified from share-count changes, treasury-share activity and cash-flow statements. A one-year yield cannot establish a durable shareholder-distribution policy.